Oakbrook Investments LLC cut its holdings in Amgen, Inc. (NASDAQ:AMGN) by 6.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 203,389 shares of the medical research company’s stock after selling 12,925 shares during the period. Amgen accounts for 2.4% of Oakbrook Investments LLC’s investment portfolio, making the stock its 3rd biggest position. Oakbrook Investments LLC’s holdings in Amgen were worth $37,922,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AMGN. Baker Ellis Asset Management LLC bought a new position in Amgen in the 3rd quarter valued at $108,000. TrimTabs Asset Management LLC boosted its holdings in Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the period. Phocas Financial Corp. bought a new position in Amgen in the 2nd quarter valued at $110,000. Jackson Grant Investment Advisers Inc. boosted its holdings in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5 shares during the period. Finally, Omnia Family Wealth LLC boosted its holdings in Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 147 shares during the period. 78.46% of the stock is owned by institutional investors.

Several research analysts have commented on AMGN shares. Cann reissued a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer reissued a “buy” rating and issued a $203.00 price target on shares of Amgen in a report on Thursday, September 7th. Royal Bank of Canada started coverage on shares of Amgen in a report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price target for the company. BMO Capital Markets reissued a “hold” rating and issued a $199.00 price target on shares of Amgen in a report on Monday, September 25th. Finally, Jefferies Group reissued a “buy” rating and issued a $200.00 price target on shares of Amgen in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $190.22.

In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the transaction, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,575 shares of company stock worth $1,509,339. Corporate insiders own 0.19% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $177.11 on Thursday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The firm has a market cap of $129,890.00, a price-to-earnings ratio of 14.00, a PEG ratio of 2.55 and a beta of 1.36. Amgen, Inc. has a 52-week low of $145.12 and a 52-week high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter last year, the company posted $3.02 EPS. sell-side analysts expect that Amgen, Inc. will post 12.66 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.98%. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is 41.55%.

Amgen declared that its Board of Directors has approved a share repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/21/oakbrook-investments-llc-has-37-92-million-position-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.